Obinutuzumab
Showing 1 - 25 of 177
Obinutuzumab, Rapid Infusion, Intravenous Infusion Reaction Trial in Nanjing (intravenous rapid infusion of obinutuzumab)
Recruiting
- Obinutuzumab
- +2 more
- intravenous rapid infusion of obinutuzumab
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital
Aug 18, 2022
Mantle Cell Lymphoma, Non-hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in Madison (Bendamustine, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- +2 more
- Bendamustine
- Obinutuzumab
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Mar 7, 2022
Chronic Lymphocytic Leukemia Trial in Milano (Ibrutinib and obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Ibrutinib and obinutuzumab
-
Milano, MI, ItalyStrategic Research Program on CLL
Apr 2, 2022
Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) Trial (parsaclisib, rituximab, obinutuzumab)
Withdrawn
- Follicular Lymphoma ( FL)
- Marginal Zone Lymphoma (MZL)
- parsaclisib
- +2 more
- (no location specified)
Jul 14, 2022
Childhood Nephrotic Syndrome Trial (Obinutuzumab, MMF, Prednisone)
Not yet recruiting
- Childhood Nephrotic Syndrome
- Obinutuzumab
- +5 more
- (no location specified)
Nov 23, 2022
Primary CNS Lymphoma Trial in Stuttgart (Venetoclax, Obinutuzumab)
Terminated
- Primary CNS Lymphoma
- Venetoclax
- Obinutuzumab
-
Stuttgart, Baden-Württemberg, GermanyKlinikum Stuttgart
Jan 18, 2022
Leukemia, Lymphocytic, Chronic Trial run by the NCI (rhIL-15, Obinutuzumab)
Terminated
- Leukemia
- +3 more
- rhIL-15
- Obinutuzumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 11, 2022
Leukemia Trial in Houston (Pirtobrutinib, Obinutuzumab, Venetoclax)
Not yet recruiting
- Leukemia
- Pirtobrutinib
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 7, 2022
Leukemia, Lymphocytic, Chronic, B-Cell Trial in New York (Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection)
Not yet recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Zanubrutinib Pill
- +2 more
-
New York, New YorkWeill Cornell Medicine/NewYork-Presberteryian Hospital
Dec 6, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the National Cancer Institute (NCI) (Venetoclax, Ibrutinib, Prednisone)
Recruiting
- Lymphoma
- +3 more
- Venetoclax
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 20, 2022
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Houston (Acalabrutinib, Obinutuzumab)
Recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- Obinutuzumab
-
Houston, TexasM D Anderson Cancer Center
Jul 14, 2022
Primary Focal Segmental Glomerulosclerosis Trial in Rochester (Obinutuzumab)
Recruiting
- Primary Focal Segmental Glomerulosclerosis
- Obinutuzumab
-
Rochester, MinnesotaMayo Clinic in Rochester
Dec 13, 2021
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)
Recruiting
- Follicular Lymphoma
- +4 more
- Obinutuzumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 20, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Nanjin (Orelabrutinib, Obinutuzumab, Fludarabine)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Orelabrutinib
- +3 more
-
Nanjin, Jiangsu, ChinaDepartment of Haematology, the First Affiliated Hospital of Nanj
Apr 12, 2022
Follicular Lymphoma Trial in Australia (Obinutuzumab 25 MG/1 ML Intravenous Solution, Atezolizumab 1200 MG/40mL Intravenous
Recruiting
- Follicular Lymphoma
- Obinutuzumab 25 MG/1 ML Intravenous Solution
- +2 more
-
Ballarat, Victoria, Australia
- +3 more
Jul 28, 2022
Lymphoma, Non-Hodgkin Lymphoma, DLBCL Trial run by the NCI (obinutuzumab, prednisone, Revlimid)
Recruiting
- Lymphoma
- +3 more
- obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Mantle Cell Lymphoma, Refractory Lymphoma Trial in Boston (Acalabrutinib, Venetoclax, Obinutuzumab)
Recruiting
- Mantle Cell Lymphoma
- Refractory Lymphoma
- Acalabrutinib
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 8, 2022
Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)
Recruiting
- Follicular Lymphoma
- Venetoclax
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medical Center
Nov 12, 2021
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Columbus (Acalabrutinib, Obinutuzumab, Venetoclax)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Acalabrutinib
- +2 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Apr 13, 2022
Chronic Lymphocytic Leukemia Trial in Boston, Rochester, Durham (Obinutuzumab, Ibrutinib)
Active, not recruiting
- Chronic Lymphocytic Leukemia
- Obinutuzumab
- Ibrutinib
-
Boston, Massachusetts
- +3 more
Jan 3, 2022
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Portland (Ibrutinib, Obinutuzumab)
Completed
- Recurrent Mantle Cell Lymphoma
- Refractory Mantle Cell Lymphoma
- Ibrutinib
- Obinutuzumab
-
Portland, OregonOHSU Knight Cancer Institute
Dec 10, 2021
Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Germany (Obinutuzumab)
Terminated
- Chronic Lymphocytic Leukemia
- Richter's Transformation
- Obinutuzumab
-
Bonn, Germany
- +6 more
Dec 16, 2021
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in
Recruiting
- Recurrent Chronic Lymphocytic Leukemia
- +3 more
- Acalabrutinib
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 17, 2022
Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial
Suspended
- Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
- Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
- Obinutuzumab
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)
Terminated
- Mantle Cell Lymphoma
- Obinutuzumab
-
Warszawa, Poland
- +1 more
Dec 23, 2021